<DOC>
	<DOCNO>NCT01090505</DOCNO>
	<brief_summary>The purpose study determine whether S-1 oxaliplatin neoadjuvant chemotherapy may improve survival benefit compare control .</brief_summary>
	<brief_title>Study S-1 Oxaliplatin Neoadjuvant Chemotherapy Locally Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . DISEASE CHARACTERISTICS : Histologically confirm gastric adenocarcinoma Locally advance disease : Clinical stage T34 , N03 , M0 ( accord Japanese gastric cancer classification ) 2 . Planning undergo gastric cancer D2 surgery neoadjuvant chemotherapy 3 . Age:20 75 4 . Performance status : ECOG 02 5 . Life expectancy : Not specify 6 . Hematopoietic : WBC 4,00012,000/mm^3；Granulocyte count ≥ 2,000/mm^3；Platelet count ≥ 100,000/mm^3；Hemoglobin ≥ 9.0 g/dL ; Hepatic : AST ALT ≤ 100 U/L；Bilirubin ≤ 1.5 mg/dL 7 . Adequate organ function 8 . Able swallow oral medication 9 . Written inform consent 1 . Synchronous metachronous ( within 5 year ) malignancy carcinoma situ 2 . Pregnant breastfeed woman 3 . Severe mental disease 4 . Systemic administration corticosteroid , flucytosine , phenytoin warfarin 5 . Other severe complication paralytic ileus , intestinal pneumonitis , pulmonary fibrosis , ischemic heart disease 6 . Myocardial infarction within six diseasefree month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>